Search company, investor...
Brickell Biotech company logo

Brickell Biotech

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Brickell Biotech

Brickell Biotech is a clinical-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of skin diseases. Brickell's development strategy includes: rapidly and cost-effectively developing product candidates, executing strategic partnerships, maintaining a diversified product portfolio that addresses unmet medical needs, and leveraging professional relationships with professionals and contract research organizations in the pharmaceutical industry.

Headquarters Location

5777 Central Avenue Suite 102

Boulder, Colorado, 80301,

United States


Missing: Brickell Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Brickell Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Brickell Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Brickell Biotech is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Brickell Biotech Patents

Brickell Biotech has filed 7 patents.

The 3 most popular patent topics include:

  • Amines
  • H1 receptor antagonists
  • Muscarinic antagonists
patents chart

Application Date

Grant Date


Related Topics




Muscarinic antagonists, Quaternary ammonium compounds, Piperidines, Amines, H1 receptor antagonists


Application Date


Grant Date



Related Topics

Muscarinic antagonists, Quaternary ammonium compounds, Piperidines, Amines, H1 receptor antagonists



Latest Brickell Biotech News

Hyperhidrosis Treatment Market Gains Momentum as Secondary Hyperhidrosis Grows Prevalent, Botulinum Toxin A Will be Sought-after

Dec 27, 2022

Pune, INDIA London, Dec. 27, 2022 (GLOBE NEWSWIRE) -- An upcoming market intelligence study of Fairfield Market Research of global hyperhidrosis treatment market would comprise a multifaceted analysis of the current growth scenario of the market. The report intends to provide a thorough assessment of how the market will perform over the near term. Global hyperhidrosis treatment market has been progressing on the back of the consistently growing burden of primary hyperhidrosis that in turn generates demand for an effective treatment for the disease. The report however points to the fact that there has been a remarkable rise in the rate of prevalence of secondary hyperhidrosis over the past decade. This is expected to predominantly drive the growth of hyperhidrosis treatment market during the considered period of projection, i.e., 2022 – 2029. Get the Sample Copy/TOC of Hyperhidrosis Treatment Market at: Insights into Segmental Analysis In the wake of the rapid spread of sedentary modern lifestyle, unhealthy dietary patterns, and consequently rising prevalence of chronic health conditions like anxiety, hyperthyroidism, and hypoglycaemia, the cases of secondary generalized hyperhidrosis have been increasing faster against the number of cases of primary focal hyperhidrosis. The report thus primarily indicates dominance of primary hyperhidrosis segment by disease type but foresees higher market attractiveness for the secondary hyperhidrosis segment through 2029. On the other hand, based on the type of treatment, botulinum toxin A remains a prominent segment on the back of a more lasting impact, and higher effectiveness. Botulinum toxin type A injections remain a preferred non-invasive surgical procedure for primary focal hyperhidrosis and axillary hyperhidrosis treatment that lasts longer than topical treatments. It is often recommended for treating abnormally excessive sweating of hands and feet, in the armpits, face and head, as well as other areas of the body. Allergen Inc’s BOTOX has been the most researched and sought-after botulinum toxin across the world, marks the report. Insights into Regional Analysis On account of the consistently piling burden of primary hyperhidrosis, North America continues to lead its way in global hyperhidrosis treatment market. While the rate of diseases diagnosis here has been higher, the highly sophisticated healthcare system and infrastructure will remain instrumental to the build-up of hyperhidrosis treatment market in North America. The US spearheads, says the primary report findings, majorly banking on the widespread availability of public and private research funds. Around 3% of the population is currently living with hyperhidrosis in the US alone, pushing the consumption of an over-the-counter product aluminum chloride hexahydrate by 20% in 2021. The market here also leverages strong presence of some of the leading industry players. In addition to better awareness levels regarding safer medicine, the region will gain significantly from increasing emphasis on precision medicine. The US market is especially expected to benefit from accelerating pace of R&D activity eying effective hyperhidrosis treatment. Several innovative products continue to debut the hyperhidrosis treatment market space in the US, which will remain among the strong push factors for the expansion of market here. For instance, a research experiment on the effectiveness of a topical product (2019) affirmed reduced severity of sweating, sweat production, and sweat toleration. Key companies like Dermira, Inc. frequently introduce innovative hyperhidrosis treatment products for both pediatric and adult patients, thereby supporting market growth. R&D continues to flourish and will play a vital role in boosting the value growth of hyperhidrosis treatment market of North America. Key Competitors in Global Hyperhidrosis Treatment Market GlaxoSmithKline plc, Sientra, Inc., Dermira, Inc, AbbVie, Inc., Ulthera, Inc., Allergan, Inc., Revance Therapeutics, Inc., Brickell Biotech, Inc., TheraVida, Inc., and Brickell Biotech, Inc. are some of the significant players steering the competition landscape of global hyperhidrosis treatment market. The report would shed light on the strategic competitive profiling and analysis of industry leaders. Do You Have Any Query or Specific Requirement? Request for Custom Research: Global Hyperhidrosis Treatment Market is Segmented as Below: By Treatment Type

Brickell Biotech Frequently Asked Questions (FAQ)

  • When was Brickell Biotech founded?

    Brickell Biotech was founded in 2009.

  • Where is Brickell Biotech's headquarters?

    Brickell Biotech's headquarters is located at 5777 Central Avenue, Boulder.

  • What is Brickell Biotech's latest funding round?

    Brickell Biotech's latest funding round is IPO.

  • How much did Brickell Biotech raise?

    Brickell Biotech raised a total of $26.09M.

  • Who are the investors of Brickell Biotech?

    Investors of Brickell Biotech include Paycheck Protection Program, Vical, Palisade Capital Management, Amorepacific Ventures, Charles Stiefel and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.